aetherAI vs Proscia Concentriq
A US lab choosing a primary-diagnosis viewer has two cleared options, and the scanner fleet decides between them. aetherSlide's 510(k) K233126 names only the Philips Ultra Fast Scanner and the PS27QHDCR monitor, and the indication carries no AI claim. Proscia's Concentriq AP-Dx has two 510(k)s. K230839 from February 2024 covers the Hamamatsu NanoZoomer S360MD, and K261380 from August 2026 adds the Leica Aperio GT 450 DX, cloud deployment and a change control plan, according to press coverage. Proscia announced SOC 2 Type II in December 2025, states ISO 27001 and ISO 13485, and claims 4,000-plus hospitals and clinics. Agilent announced an agreement to acquire Proscia on October 13, 2026, pending, with closing expected early in Agilent's fiscal 2027.
A lab on Leica or Hamamatsu scanners gets a cleared pairing from Proscia, so aetherAI is the wrong buy there. A lab on Philips scanners is aetherAI's buyer.
Pathology · Reviewed November 2, 2026
aetherAI
by aetherAI · founded 2015
FDA-cleared slide viewer for hospital pathology labs. Bone marrow and colon polyp AI modules are TFDA approved in Taiwan.
Proscia Concentriq
by Proscia
Concentriq pathology platform for clinical labs and biopharma: image management, case review and AI apps, with FDA-cleared AP-Dx for primary diagnosis.
When to pick each one
aetherAI
- Cleared with Philips Ultra Fast Scanner and PS27QHDCR monitor
- Slide viewer, no AI claim in the cleared indication
Proscia Concentriq
- Two 510(k)s, Hamamatsu then Leica Aperio GT 450 DX
- SOC 2 Type II announced December 2025
Score
Each row shows points earned of points available under the published rubric.
aetherAI
51of 100
Proscia Concentriq
40of 100
| Dimension | aetherAI | Proscia Concentriq | Difference |
|---|---|---|---|
| FDA clearance | 18 / 18 | 18 / 18 | 0 |
| HIPAA / SOC2 / BAA | 0 / 10 | 6 / 10 | -6 |
| EHR integrations (count) | 0 / 4.2 | 0 / 4.2 | 0 |
| Top-3 EHR coverage (Epic / Oracle / Athena) | 0 / 2.4 | 0 / 2.4 | 0 |
| Peer-reviewed papers | 14.7 / 21 | 0 / 21 | +14.7 |
| RCT / meta-analysis / systematic review | 0 / 7.8 | 0 / 7.8 | 0 |
| Funding & adoption signal | 3 / 12 | 8.4 / 12 | -5.4 |
| Pricing transparency | 2.5 / 5 | 2.5 / 5 | 0 |
| Years in market | 6 / 6 | 0 / 6 | +6 |
Scroll horizontally to see every column.
Pricing
aetherAI
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. |
Proscia Concentriq
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. Demo request only. |
Evidence
aetherAI
FDA decisions
K233126 (opens in new tab)510(k)2024-05-30
aetherSlide
Peer-reviewed
2 PubMed records name aetherAI.
Proscia Concentriq
FDA decisions
K261380 (opens in new tab)510(k)2026-08-05
Concentriq AP-Dx
K230839 (opens in new tab)510(k)2024-02-08
Concentriq Dx (marketed as Concentriq AP-Dx)
Compliance and integrations
Documented from each vendor’s own pages.
| Spec | aetherAI | Proscia Concentriq |
|---|---|---|
| Free tier | ||
| HIPAA | ||
| SOC 2 Type II | ||
| EHR integrations | Not specified | Not specified |
| Founded | 2015 | n/a |
| HQ | TW | n/a |
Scroll horizontally to see both columns.
Common questions
Open the full pathology comparison
Digital pathology workflows with FDA-cleared cancer detection (prostate, breast, colon), IHC scoring (HER2, Ki67), and AI-powered image management. Tempus, PathAI, Proscia dominate.